ExploreWatchlistsPricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Long-term debt, non-current

Carna Biosciences, Inc. (4572)

Market cap
¥6B
P/E ratio
-2.9x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndLong-term debt, non-current (Million JPY)YoY (%)

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat